The American Society for Radiation Oncology has announced the classification of stereotactic body radiation therapy as a first-line treatment option for prostate cancer.
As a first-line treatment, SBRT can be considered a primary form of treatment for prostate cancer. The results of long-term clinical trials supporting the safety and efficacy of stereotactic body radiation in treating prostate cancer led ASTRO to announce the decision. The results of clinical studies show patient outcomes with SBRT are at least as good as other forms of radiotherapy treatments.
Philadelphia CyberKnife performs SBRT using CyberKnife® technology. During the procedure, the CyberKnife delivers precisely targeted, high-dose radiation beams to the prostate. CyberKnife treatment is painless and requires no cutting or sedation. Patients are treated in five or fewer sessions and experience few to no side effects.
ASTRO classifies treatments into first- and second-line options to help define coverage policies for various radiation oncology services. Read more about more ASTRO’s policy on SBRT here.
Philadelphia CyberKnife is pleased with this exciting milestone! For more information about the benefits of SBRT in treating prostate cancer, click here.